430 related articles for article (PubMed ID: 25838441)
1. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
Brower V
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
[No Abstract] [Full Text] [Related]
2. Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G; Klinger M; Schmidt M; Subklewe M
Mol Immunol; 2015 Oct; 67(2 Pt A):58-66. PubMed ID: 25883042
[TBL] [Abstract][Full Text] [Related]
3. Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.
Lejeune M; Köse MC; Duray E; Einsele H; Beguin Y; Caers J
Front Immunol; 2020; 11():762. PubMed ID: 32457743
[TBL] [Abstract][Full Text] [Related]
4. Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies.
Burt R; Warcel D; Fielding AK
Hum Vaccin Immunother; 2019; 15(3):594-602. PubMed ID: 30380973
[TBL] [Abstract][Full Text] [Related]
5. CAR T-cells merge into the fast lane of cancer care.
Frey NV; Porter DL
Am J Hematol; 2016 Jan; 91(1):146-50. PubMed ID: 26574400
[TBL] [Abstract][Full Text] [Related]
6. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
7. [Bispecific antibodies in onco-hematology: Applications and perspectives].
Barrière S; El-Ghazzi N; Garcia M; Guièze R
Bull Cancer; 2021 Oct; 108(10S):S195-S204. PubMed ID: 34920803
[TBL] [Abstract][Full Text] [Related]
8. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
9. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
10. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Braendstrup P; Levine BL; Ruella M
Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
[TBL] [Abstract][Full Text] [Related]
11. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
Lorentzen CL; Straten PT
Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
[TBL] [Abstract][Full Text] [Related]
12. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
13. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials with blocked ricin immunotoxins.
O'Toole JE; Esseltine D; Lynch TJ; Lambert JM; Grossbard ML
Curr Top Microbiol Immunol; 1998; 234():35-56. PubMed ID: 9670611
[No Abstract] [Full Text] [Related]
15. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
Stieglmaier J; Benjamin J; Nagorsen D
Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
[TBL] [Abstract][Full Text] [Related]
16. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Hill JA; Li D; Hay KA; Green ML; Cherian S; Chen X; Riddell SR; Maloney DG; Boeckh M; Turtle CJ
Blood; 2018 Jan; 131(1):121-130. PubMed ID: 29038338
[TBL] [Abstract][Full Text] [Related]
17. Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.
Advani AS
Clin Adv Hematol Oncol; 2011 Oct; 9(10):776-7. PubMed ID: 22252580
[No Abstract] [Full Text] [Related]
18. CAR therapy: the CD19 paradigm.
Sadelain M
J Clin Invest; 2015 Sep; 125(9):3392-400. PubMed ID: 26325036
[TBL] [Abstract][Full Text] [Related]
19. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
20. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
